Blueprint Medicines Corp’s filing revealed that its CHIEF SCIENTIFIC OFFICER Carter Percy H. unloaded Company’s shares for reported $0.34 million on Jun 03 ’25. In the deal valued at $127.88 per share,2,659 shares were sold. As a result of this transaction, Carter Percy H. now holds 54,206 shares worth roughly $6.96 million.
Then, Albers Jeffrey W. sold 5,000 shares, generating $505,692 in total proceeds. Upon selling the shares at $101.14, the Director now owns 146,630 shares.
Before that, Albers Jeffrey W. bought 5,000 shares. Blueprint Medicines Corp shares valued at $505,686 were divested by the Director at a price of $101.14 per share.
Wedbush downgraded its Blueprint Medicines Corp [BPMC] rating to a Neutral from a an Outperform in a research note published recently. Wolfe Research began covering BPMC with “an Outperform” recommendation on March 18, 2025. Jefferies started covering the stock on March 17, 2025. It rated BPMC as “a Buy”.
Price Performance Review of BPMC
On Thursday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 0.12% to $128.35. Over the last five days, the stock has gained 0.16%. Blueprint Medicines Corp shares have risen nearly 17.56% since the year began. Nevertheless, the stocks have risen 47.16% over the past one year. While a 52-week high of $128.52 was reached on 07/01/25, a 52-week low of $73.04 was recorded on 04/09/25.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 128.23, which if violated will result in even more drops to 128.12. On the upside, there is a resistance level at 128.43. A further resistance level may holdings at 128.52.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-06-13, dropping by -2.54 million shares to a total of 3.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 5.67 million shares. There was a decline of -81.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $150 price target.
